Atopic Dermatitis
9
Companies
13
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Regeneron Pharmaceuticals, Inc.
Dupixent
Galderma Group AG/ADR
CD5024 0.3% cream
Aclaris Therapeutics, Inc.
ATI-502
Aclaris Therapeutics, Inc.
ATI-045
Aclaris Therapeutics, Inc.
ATI-1777
Aclaris Therapeutics, Inc.
ATI-1777 2.0% w/w
Aclaris Therapeutics, Inc.
ATI-2138
Johnson & Johnson
Experimental Product 1% Colloidal Oatmeal Balm
Forte Biosciences, Inc.
FB-401
VYNE Therapeutics Inc.
FMX114
Incyte Corporation
Ruxolitinib 0.15% Cream QD
Kymera Therapeutics, Inc.
KT-621
AnaptysBio, Inc.
Placebo
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | Dupixent | Approved | — | — | — |
| GALDY Galderma Group AG/ADR | CD5024 0.3% cream | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-502 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-045 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-1777 | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-1777 2.0% w/w | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | ATI-2138 | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | — | — | — |
| FBRX Forte Biosciences, Inc. | FB-401 | Phase 2 | — | — | — |
| VYNE VYNE Therapeutics Inc. | FMX114 | Phase 2 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib 0.15% Cream QD | Phase 2 | — | — | — |
| KYMR Kymera Therapeutics, Inc. | KT-621 | Phase 2 | — | — | — |
| ANAB AnaptysBio, Inc. | Placebo | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.